Gentamicin protection assays were used to assess: (A) C57BL/6 BMDC phagocytosis of WT P. aeruginosa strain PA14, the independent mucoid clinical isolate FRD1, and increasing concentrations of non-flagellated mutant flgK and flagellated but non-swimming mutant motABmotCD (in PA14 background). (B) Murine BMDC phagocytosis of WT V. cholerae strain O395, and the flaA, motX, tcpA, and toxT mutants. (C) Murine BMDC phagocytosis of WT E. coli strain K12, and the flgK, fliC, and motA mutants. (D) Human THP-1 leukocyte phagocytosis of P. aeruginosa WT, flgK, and motABmotCD (left); or V. cholerae WT, flaA, and motX (right). Where indicated throughout this and the other figures, phagocytosis of WT strains (PA14, K12 and 0395 in this figure) has been normalized to 100% and the relative phagocytosis of the mutant strains shown as the percent of WT. N≥6, *p<0.05 compared to WT.